Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    xyz-pharma-2025-04-21

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Menu

    Olutasidenib

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Rigel Enrolls First Patient in Phase 1b/2 Trial of REZLIDHIA® in mIDH1 AML
    Rigel Enrolls First Patient in Phase 1b/2 Trial of REZLIDHIA® in mIDH1 AML

    05 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/rigel-announces-first-patient-enrolled-in-phase-1b2-triplet-therapy-trial-of-rezlidhia-olutasidenib-in-midh1-aml-302238788.html

    PR NEWSWIRE
    05 Sep 2024
    Share Share
    Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update
    Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update

    06 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/rigel-reports-second-quarter-2024-financial-results-and-provides-business-update-302215852.html

    PR NEWSWIRE
    06 Aug 2024
    Share Share
    Rigel Announces Publication of Data on REZLIDHIA in Post-Venetoclax Patients
    Rigel Announces Publication of Data on REZLIDHIA in Post-Venetoclax Patients

    04 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/rigel-announces-publication-of-data-on-rezlidhia-olutasidenib-in-post-venetoclax-patients-with-mutant-idh1-aml-in-leukemia--lymphoma-302107833.html

    PR NEWSWIRE
    04 Apr 2024
    Share Share
    Rigel Announces Collaboration with CONNECT to Conduct Phase 2 of Olutasidenib
    Rigel Announces Collaboration with CONNECT to Conduct Phase 2 of Olutasidenib

    04 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/rigel-announces-collaboration-with-connect-to-conduct-a-phase-2-trial-of-olutasidenib-in-glioma-302026029.html

    PR NEWSWIRE
    04 Jan 2024
    Share Share
    Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance
    Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance

    08 Dec 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/rigel-pharmaceuticals-and-md-anderson-announce-strategic-alliance-to-advance-rezlidhia-olutasidenib-in-aml-and-other-cancers-302009825.html

    PR NEWSWIRE
    08 Dec 2023
    Share Share
    Rigel Announces Presentation of Data from Analysis of REZLIDHIA
    Rigel Announces Presentation of Data from Analysis of REZLIDHIA

    07 Jun 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/rigel-announces-presentation-of-data-from-analysis-of-rezlidhia-olutasidenib-in-post-venetoclax-patients-with-mutant-idh1-aml-301844657.html

    PR NEWSWIRE
    07 Jun 2023
    Share Share